Despite the progress in immunosuppressive drugs to manage and minimize organ rejection
after transplantation, infectious complications remain a major cause of morbidity. 1 Infections
such as herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV) have been
successfully controlled through the deployment of prophylactic acyclovir or its prodrug
valaciclovir, 2, 3 whereas prophylactic and preemptive therapy with valganciclovir has been
instrumental in managing human cytomegalovirus (HCMV) infections. 4, 5 However, the …